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Background 1 
Pneumococcal conjugate vaccines (PCVs) have now been included into most national childhood 2 
immunisation programmes worldwide [1], primarily to reduce morbidity and mortality during 3 
childhood [2]. A striking feature of national PCV infant immunisation programmes, however, has 4 
been the added benefit of herd protection [3,4] which has led to near elimination of vaccine 5 
serotype (VT) disease within a few years after PCV introduction [5]. This indirect benefit is 6 
particularly relevant in high income settings where a substantial proportion of vaccine preventable 7 
pneumococcal disease occurs among older individuals.  8 
PCVs, however, only target a small subset of the more than 90 pneumococcal serotypes. Hence, PCV 9 
use created an ecological niche that was instantaneously filled by untargeted serotypes (serotype 10 
replacement) [6], and mitigated some of the their impact [5]. To circumvent the problem of 11 
replacement disease, several vaccine candidates are being developed. Some aim to expand the 12 
serotype coverage of current PCVs to serotypes that are the primary cause of replacement disease. 13 
Other approaches, including whole cell vaccines and common protein vaccines, aim at capsule-14 
independent protection against all pneumococci [7], either to be used in combination with PCVs or 15 
as an alternative. A benefit of candidates without a PCV component is that those avoid the costly 16 
conjugation process. Hence, they can improve affordability of pneumococcal vaccines which is of 17 
much concern to many low and middle income countries in particular. 18 
In a recent phase II trial the most advanced of those vaccine candidates, a PCV combined with 19 
pneumolysin toxoid and pneumococcal histidine triad protein D, failed to demonstrate any efficacy 20 
against carriage of serotypes not targeted by the PCV [8]. In particular for candidates in the 21 
pneumococcal vaccine pipeline that do not include a PCV component this raises a strategic question: 22 
“can a pneumococcal vaccine that only provides direct protection offset the lack of indirect 23 
protection with the benefit of additional direct protection against serotypes untargeted by current 24 
PCVs?” 25 
In the following we assess the scope of pneumococcal vaccines that target the whole species and act 26 
to reduce disease risk but do not affect transmission. 27 
 28 
Methods 29 
Data 30 
Currently two PCV formulations are available, a 13-valent PCV (PCV13) and a 10-valent PCV (PCV10) 31 
that targets a subset of PCV13’s serotypes. We selected a convenience sample of four sites with 32 
robust surveillance for invasive pneumococcal disease (IPD) spanning at least 3 years before PCV 33 
introduction to at least 3 years after introduction. We selected Kilifi, Kenya [9] to represent a low-34 
income PCV10 setting, the Gambia as a low income PCV13 setting [10], the Netherlands as a high 35 
income PCV10 setting [11] and England and Wales (E&W) as a high income PCV13 setting [12]. For 36 
each setting age-stratified incidence risk ratios (IRRPCV) for all serotype IPD incidence during PCV10 or 37 
PCV13 use in comparison with pre PCV were extracted. In the Gambia, the Netherlands and E&W the 38 
seven valent PCV (PCV7) had been in use before the current formulation. For both the Gambia and 39 
E&W the IRRs of PCV13 use in comparison with no vaccination were reported. For the Netherlands 40 
we multiplied reported IRRs to obtain the IRR of 3 years post PCV10 to early post PCV10 to pre 41 
PCV10 to pre PCV7. For Kilifi, Kenya we calculated the IRR based on reported 2008-2010 IPD 42 
incidence before PCVs and 2011-2015 incidence during PCV use. 43 
Analyses 44 
Clearly, a vaccine against all pneumococcal serotypes that does not limit transmission will need high 45 
clinical efficacy and a reasonable duration of vaccine protection to be competitive. We compared 46 
the impact of PCVs to the potential impact of a hypothetical pneumococcal vaccine candidate 47 
(HPVC) that acts to reduce the risk for IPD caused by any serotype by 90% for 5 years after 48 
vaccination and to lose its protective effect immediately thereafter. Based on typical DTP3 vaccine 49 
coverage in low and high income countries [13] we assumed that such vaccine can be administered 50 
to immunise 75% and 95% of young infants in low and high income settings respectively. The 51 
predicted impact of HPVC was calculated as IRRHPVC = 1 – (vaccine efficacy * vaccine coverage) for all 52 
age bands including children up to 5 years old. The predicted impact of combined use of PCV and 53 
HPVC was calculated as IRRPCVHPVC = IRRPCV * IRRHPVC. 54 
 55 
Results 56 
Low and high income countries differ substantially in which age groups contribute most to the 57 
overall burden of pneumococcal disease, in parts a result of differences in their demographic profile 58 
and life expectancy. Before the introduction of PCV in Kenya and the Gambia over 60% of IPD cases 59 
were reported among children younger than 5 years old. In contrast, IPD in children of that age in 60 
E&W and the Netherlands only accounted for less than 15% of all IPD (Figure 1 and Table 1). 61 
Consequently, among all IPD cases averted through PCVs use less than 25% and more than 75% have 62 
been averted among <5 year old children from the two high and the two low income countries 63 
respectively. 64 
We estimate that in Kenya and the Gambia the HPVC could prevent 44% and 47% of all IPD while in 65 
E&W and the Netherlands it could only prevent 10% and 6%. In comparison, PCV was reported to 66 
prevent only slightly more IPD cases than that in the two low income settings, however, substantially 67 
more in the two high income settings (Figure 1). If assessed against the impact of routine PCV use 68 
against all IPD we find that use of a combined PCV and HPVC vaccine would add little impact in the 69 
two high income settings while it may offer substantial additional protection in the two low income 70 
countries. 71 
When focussing on the impact in young children HPVC compares more favourably. In all four settings 72 
we predict that HPVC would be superior, if compared to the observed impact of PCV on IPD in young 73 
children (Figure 2). We predict that HPVC could prevent 67.5% and 85.5% of childhood IPD in the low 74 
and high-income settings respectively. If given in combination with PCV, this impact could be 75 
increased to about 85% and 95% in the low and high-income settings respectively. 76 
 77 
Discussion 78 
National PCV infancy programmes have substantially reduced the pneumococcal disease burden. In 79 
particular in high income settings, much of that reduction can be attributed to indirect protection by 80 
limiting VT transmission. While vaccine candidates that do not prevent pneumococcal carriage will 81 
not induce such indirect protection, they may protect against disease from all pneumococci and will 82 
not cause serotype replacement. We show here that such candidate vaccine, if found highly 83 
protective against disease and given early in infancy can have similar or even superior impact among 84 
young children compared with PCVs. However, in high income settings the majority of the 85 
population impact of PCVs stems from the prevention of adult and elderly disease. Hence, HPVC use 86 
in such settings is likely to only achieve a small fraction of PCV’s population impact. 87 
Vaccines that target all pneumococci at once are designed with the ultimate goal to prevent the 88 
majority if not all pneumococcal disease. Pneumococcal vaccines that do not limit transmission will 89 
not achieve such goal. In fact, we show that even at high coverage and at high clinical efficacy they 90 
are likely to offer comparable population impact only in those settings where much of the 91 
pneumococcal disease burden is concentrated in young children. However, these settings are 92 
typically low income settings which also would benefit most from a major advantage of HPVC: they 93 
may be manufactured at a fraction of the costs of PCVs. In the near future many low income 94 
countries will need to take over the full costs of their pneumococcal vaccine programmes which are 95 
currently mainly paid for by Gavi, the Vaccine Alliance [14]. To continue PCV use some would need 96 
to more than double their current vaccine budget. An option to reduce pneumococcal vaccine costs 97 
while sustaining similar impact could be the decisive factor for programme sustainability in these 98 
settings [15].   99 
Unless supplemented by additional vaccination programmes, settings with a high disease burden in 100 
older individuals, like most high income countries, likely favour the indirect effects of the infant PCV 101 
programme over the added protection of HPVC in young children. In those settings a combined PCV 102 
and HPVC approach may offer an alternative use for HPVC. HPVCs can further reduce the residual 103 
childhood burden of pneumococcal disease and hence counter-act serotype replacement following 104 
PCV use. However, we estimate that combined PCV and HPVC use in the two high income settings 105 
may only prevent an additional 1-3% of all pneumococcal IPD and as a result would only achieve a 106 
similar cost-effectiveness profile to PCVs if HPVC can be used to immunise children at less than 5% of 107 
PCV costs. 108 
Conducting a phase III trial with targeted clinical efficacy of about 90% for a vaccine that was found 109 
not to protect against pneumococcal carriage may need a leap of faith. In consolation though, 110 
aiming to detect only high efficacy comes with the advantage that it reduces the required sample 111 
size and, if successful, may offer a key tool for prevention of pneumococcal disease in low income 112 
settings. A further caveat is that the vaccine candidate will need to demonstrate that it protects not 113 
only against the most severe disease but also against non-bacteraemic pneumonia and otits media 114 
which substantially contribute to the pneumococcal disease burden.  115 
In conclusion, the success of PCVs has set a high benchmark for future pneumococcal vaccines. 116 
However, a vaccine against all pneumococci with high clinical efficacy and a moderate duration of 117 
protection given to young infants could help sustain or even further reduce the pneumococcal 118 
childhood disease burden in low income countries and at more sustainable costs, even if it fails to 119 
induce indirect protection. 120 
 121 
Declaration of interest 122 
Dr. Flasche has nothing to disclose. 123 
 124 
Literature 125 
[1]  International Vaccine Access Center - Johns Hokins Bloomberg School of Public Health. 126 
Global PCV introduction status n.d. 127 
[2]  O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease 128 
caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. 129 
Lancet 2009;374:893–902. 130 
[3] Pneumococcal vaccines. WHO position paper. Relev Epidemiol Hebd 1999;74:177–83. 131 
[4]  Klugman KP. Herd protection induced by pneumococcal conjugate vaccine. Lancet Glob Heal 132 
2014;2:e365–6. 133 
[5]  Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, et al. Serotype-specific 134 
changes in invasive pneumococcal disease after pneumococcal conjugate vaccine 135 
introduction: a pooled analysis of multiple surveillance sites. PLoS Med 2013;10:e1001517. 136 
[6]  Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal 137 
vaccination. Lancet 2011;6736:1–12. 138 
[7]  Alderson MR. Status of vaccine research and development of pediatric vaccines for 139 
Streptococcus pneumoniae. Vaccine 2016;34:2959–61. 140 
[8]  Odutola A, Ota MOC, Antonio M, Ogundare EO, Saidu Y, Foster-Nyarko E, et al. Efficacy of a 141 
novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of 142 
Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind 143 
study. Vaccine 2017;35:2531–42. 144 
[9]  Flasche S, Ojal J, Le Polain de Waroux O, Otiende M, O’Brien KL, Kiti M, et al. Assessing the 145 
efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a 146 
modelling study based on data from PCV10 introduction in Kilifi, Kenya. BMC Med 147 
2017;15:113. 148 
[10]  Mackenzie GA, Hill PC, Jeffries DJ, Hossain I, Uchendu U, Ameh D, et al. Effect of the 149 
introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in 150 
The Gambia: a population-based surveillance study. Lancet Infect Dis 2016;3099:1–9. 151 
[11]  Knol MJ, Wagenvoort GHJ, Sanders EAM, Elberse K, Vlaminckx BJ, de Melker HE, et al. 152 
Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal 153 
Conjugate Vaccine, the Netherlands. Emerg Infect Dis 2015;21:2040–4. 154 
[12]  Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MPE, Miller E. Effect of the 13-valent 155 
pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 156 
years after its introduction: an observational cohort study. Lancet Infect Dis 2015;3099:1–9. 157 
[13]  World Health Organization. Monitoring and Surveillance - Vaccine Coverage Estimaes n.d. 158 
[14]  Gavi The Vaccine Aliance. The transition process 2017. 159 
[15]  Flasche S, Van Hoek AJ, Goldblatt D, Edmunds WJ, O’Brien KL, Scott JAG, et al. The Potential 160 
for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd 161 
Immunity in High-Income Countries. PLOS Med 2015;12:e1001839. 162 
 163 
  164 
Figure 1: Cumulative age distribution of the proportion of IPD cases and IPD cases averted by either 165 
PCV, a hypothetical vaccine (HPVC) or their combined use. The impact of PCVs refers to the 166 
observed impact of PCV 13, 10, 10 and 13 in Gambia, Kenya, Netherlands and the UK in 167 
comparison to no vaccination. The hypothetical vaccine is assumed to be delivered to 75% 168 
of young infants and offer no indirect protection but 90% protection against all IPD for 5 169 
years.  170 
Figure 2: The proportion of IPD cases averted in children by either PCV a hypothetical vaccine (HPVC) 171 
or their combined use.  172 
Table 1: Overview of observed PCV impact across age groups in two low and two high income 173 
countries with good IPD surveillance (sites). The incidence rate ratios (RR) in all instances 174 
refer to ecological analyses of the population impact of the current PCV infant 175 
immunisation programme in comparison to no vaccination. 176 
Setting  Product in use Age group Cases before PCV PCV RR reference 
Gambia PCV13  2-11m 81 0.45 [10] 
     12-23m 71 0.45 
     2-4y 9 0.44 
     5-14y 37 0.84 
     15+y 40 0.41 
Kenya PCV10  <1y 27 0.40 [9] 
     1-5y 61 0.32 
     6-14y 17 0.45 
     15-20y 1 0.60 
     21-49y 11 0.99 
     50y+ 11 0.49 
Netherlands PCV10  <2y 75 0.15 [11] 
     2-4y 25 0.35 
     5-17y 22 0.74 
     18-49y 197 0.77 
     50-64y 273 0.88 
     65y+ 717 0.75 
E&W PCV13  <2y 710 0.23 [12] 
     2-4y 319 0.26 
     5-14y 319 0.23 
     15-44y 1839 0.31 
     45-64y 2390 0.44 
     65y+ 3045 0.6 
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